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Purpose. To establish the dependence of lipid profile changes in
patients with essential arterial hypertension (EAH) on the type of left
ventricular hypertrophy (LVH) and gene polymorphism of angiotensin-
converting enzyme (ACE, I/D) and endothelial nitric oxide synthase
(eNOS, T894G).
Design/approach. In a prospective study 120 patients with EAH I-III
severity stages: 12,5% (15) persons with EAH I, 60,0% (72) with EAH
II, 27,5% (33) with EAH III; 48,3% (58) women and 51,7% (62) men,
mean age 52,91±9,24, the disease duration from 2 to 28 years; the
control group - 20 healthy individuals were involved. Ventricular mass
(LVM) was evaluated by Echo-KG. Plasma lipids were studied by
spectrophotometer, analyzed according to the recommendations of the
ESC, ESH (2009). Genes' allele polymorphic areas of ACE (I/D), eNOS
(T894G) were set by PCR analysis.
Findings. High-risk groups of lipid profile changes in patients with
EAH is a carriers of DD-genotype of ACE gene by increasing of low
density cholesterol level and atherogenic index by 1,3 times (p<0.05).
Genetic risk of dyslipidemia in EAH patients with unfavorable eccentric
and concentric LVH and ACE and eNOS genes mutations (ID/TT, ID/
TG, DD/TG haplotypes) increases by 2,57-3,86 time (OR=2,57-3,86).
Combination of Wild I-allele of ACE gene and G-allele of eNOS gene
(II/GG, II/TG haplotypes) is protective against development of
hypercholesterolemia in patients with unfavorable patterns of LVH
(OR=0,12-0,94) and makes the chances of dyslipidemia risk the lowest
in the population of EAH patients (p=0.05).
Research limitations/implications. The study is limited by the
peculiarities of laboratory and diagnostic tests.
Originality/value. The original research without a prototype provides
pathogenetic data for early detection and prevention of metabolic
disorders in the presence/absence of LVH in patients with EAH.
© O.V. Kushnir, L.P. Sydorchuk, O.M. Iftoda, A.R. Sydorchuk, 2015
Introduction
Left ventricular hypertrophy (LVH) is one of the
key manifestations of the cardiac damage, as target-
organ at arterial hypertension (AH). LVH increases
frequency of cardio-vascular complications (CVC)
twice according to Fleming's research and works of
R.B. Devereux et al [3,11] independently of the other
risk factors (hypercholesterolemia, old age, high
office or daily AH), increases general mortality from
cardio-vascular diseases (CVD), frequency of
myocardial infarction, need in revascularization. It
has been proved that an increase of the LV wall
thickness in patients with arterial hypertension by 1
mm is associated with an increase of death risk
almost 7 times [4]. On the level with LVH disli-
pidemia is the factor that determines unfavourable
prognosis of the patient with AH. In the latest
fundamental clinical investigations  (HPS, PROVE-
IT, REVERSAL and others) it has been proved that
normalization of the general cholesterol content
(GCC) and reduction of lipoproteins cholesterol level
of low density (CL LPLD) below standard meanings
in persons with ischemic cardiac disease does not
result in complete prevention of atherosclerosis
progression and development of cardiac manifes-
tations [1, 9, 13]. It has been also proved that genetic
absence of apoprotein anoE in mice, or receptors to
LPLD is accompanied by marked lipid metabolism
impairments and spontaneous atherosclerosis deve-
lopment. However, if these changes are connected
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with absence of the receptors to angiotensin II of
type I (AGTR1), or with the use of their blockers,
then atherosclerosis development slows down sharply
in spite of hypercholesterolemia and marked
systemic lipid impairments. So, not so much GCC, as
activation of rennin-angiotensin-aldosterone system
(RAAS), mainly with the tissue one and not
circulatory, determines the development of
atherosclerotic damage [10, 12]. Combination of
dislipidemia, atherosclerosis and LVH makes signi-
ficantly worse the course of the principle disease and
patient's prognosis [1, 2, 5].
In spite of the great number of investigations,
questions of the genetic susceptibility of patients with
CVD to the development of dislipidemia through
RAAS and myocardium remodeling as a potential
target of disculatory and humoral impairments, in the
support of compensatory-adjusting mechanisms of
the pathogenetic defence in continuing AH remain
not studied nowadays. Stratification of clinico-genetic
markers, which are associated with lipid metabolism
changes and geometric models of hypertrophic
myocardium in patients with essential AH (EAH),
with the following determination of high risk groups
of dislipidemia development is also of particular
interest to our mind.
Aim of the research
To establish the dependence of lipid profile chan-
ges in patients with EAH upon LVH  type and gene
polymorphism of angiotensin-converting enzyme
(ACE, I/D) and endothelial nitric oxide synthase
(eNOS, T894G).
Materials and methods
147 patients with EAH I-III stages of severity
(ESH, 2009) [5, 7] took part in a prospective inves-
tigation. 120 patients with EAH I-III, who signed
informative agreement of a patient for taking part in
the investigation with the following blood sampling
for genetic analysis underwent screening stage.
Among patients there were 125% (15) of persons
with EAH I, 60,0% (72) - with EAH II, 27,5% (33) -
with AH III stage; 48,3% (58) were women and
51,7% (62) - men, the average age was 52,91± 9, 24
years, disease duration was from 2 till 28 years (in
average 15, 73±8,02 years). Control group consti-
tuted 20 practically healthy persons of the correspon-
ding age and gender.
Aleles of polymorfous ares I/D gene ACE and
T8946 eNOS gene were studied by means of poly-
merase chain reaction (PCR) using amplyficator
"Amply-4L" (Moscow). DNA fragments were di-
vided by gel-electrophoresis method, visualized by
means of transluminator.
Echo-KG was carried out on automated diag-
nostic complex SonoAce8000 SE ("Medison", Ko-
rea): in M- and B-regiments standard linear data of
structural-functional condition of LV, including LV
geometry were analyzed in M- and B- regimens.
Miocardium  mass of the LV (MMLV) was estima-
ted according to Penn Convention, MMLV index
(GMMLV) was calculated by correlation of MMLV
to the body surface square in g/m2; criterion of LVH
presence, according to the European recom-
mendations ESH, ESC (2007, 2009), was considered
GMMLV in men ≥125 g/m2, in women  ≥110 g/m2.
The following geometric models f the LV myocar-
dium were determined according to the indices of
GMMLV and relative thickness of the LV walls
(RTWLV): standard geometry of the LV (SG, LV),
concentric remodeling of the LV (CR LV), eccentric
hypertrophy of the LV (EH LV), concentric hypert-
rophy of the LV (CH LV). All patients also under-
went complex of examinations: ECG in 12 standard
leads USE of the kidneys and organs of the ab-
dominal cavity, general clinical and biochemical
analyses, consultations of ophthalmologists and neuro-
pathologists.
Investigations of the blood plasma lipids included
determination of general cholesterol (GCS), trigly-
cerides (triacilglycerols, TG) using "Cholesterol PAP
SL Mono" an "Triglycerides SL Mono" reagents
("Biopharma", France-Ukraine) and CS of
lipoproteins of high, low and too low density (CS
LPHD, CS LPLD, CS LPTLD) ("Biosystem" S.A.,
Spain), investigations were carried out on spect-
rophotometer ("PM", Finland), with the wave length
of 500±20mm [6]. Atherogene index (GA) was cal-
culated by A.N. Klimov's formula: GA= (GCS - CS
LPHD)/CS LPHD. According to recommendations
of ESC, ESH and Ukrainian association of cardio-
logists GCS <5,0 mmol/l, GC LPHD  <3,0 mmol/l,
GC LPHD in men >1,0 mmol/l, in women >1,2
mmol/l, TG <1,7 mmol/l [2,5], GA ≤2,5 were taken as
normal ("having a special purpose") indices
abdominal obesity was determined by means of
waist dimension for men >102 cm, for women >88
cm [5, 6]. Index of body weight (BWI kg/m2) was
measured by ratio of the body mass to height, raised
to square. BWI was considered according to the
recommendations of National Institute of Health,
USA and North-American association in obesity
study, as normal - 18,5-24,9 kg/m2, heightened mass
BWI - 25-29,9 kg/m2, obesity BWI >30 kg/m2 [8].
Statistical processing was carried out by means
of applied programmes MS® Excel® 2003™,
Primer of Biostatistics® 6.05 and Statistica® 7.0
(StatSoft Inc., USA). Indices truth for independent
selections were calculated using unpaired t-criterion
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Table 1
Lipid profile in patients with EAH depending on geometric models of the left ventricle
Geometric model 
LV 
NG LV, n=10 
(8,3%) 
CR LV, n=15 
(12,8%) 
EH LV, n=38 
(31,7%) 
CH LV, n=57 
(47,5%) 
GCS, mmol/l  5,05±0,52 5,81±0,87 6,04±0,56  6,07±0,63 
m 1,28±0,14 1,20±0,11 1,08±0,23 
1,01±0,15  
р=0,054 CS LPHD, 
mmol/l 
w 1,40±0,15 1,33±0,22 1,24±0,19 
1,20±0,13  
р=0,056 
















Notes: 1. GCS – general cholesterole; CS LPHD/LPLD – lipoproteins cholesterole  of high/low density; IA – 
atherogenicity index; M – men; W – women; NGLV -  normal geometry of the left ventricle (LV); CRLV – 
concentric remodeling of the LV; EHLV – eccentric hypertrophy of the LV; CHLV – concentric remodeling 
of the LV. 2. p – probability of indices differences relatively to NGLV; p1 – probability of differences 
indices relatively to CRLV; p2 – probability of differences indices relatively to EHLV 
 
Student (division according to Kolmogarov-Smirnov
and W-criterion Shapiro-Wilk tests were close to
normal), or U-criterion Wilcoxon-Mann-Whitney;
analyses of qualitative signs - by χ2 criterion. The
difference was considered probable at p<0,05.
Results
The content of GCS, TG, CS LPHD and IA was
probably higher in patients with EAH II-III stages
than in patients with EAH I stage and practically
healthy ones (p<0,05). CS LPHD decreased with an
increase of EAH severity, but probably only in pa-
tients with EAH III stage in women and men against
those with EAH I stage on 19,1% and 27,9%
(p<0,05) correspondingly.
As to ACE indices of lipid profile between geno-
types carries did not essentially differed, although CS
LPHD and IA in carriers of D-allele excelled those in
persons of the control group in 1,4-2,0 times (p<0,05),
and in patients with DD-genotype given indices were
higher than in homozygous patients with I-allele in 1,3
times (p<0,05). In T-allele carries of eNOS gene IA
exceeded the same in the group of control in 1,7 and
1,96 times (p<0,05) correspondingly.
Lipid profile depending on geometric myocardium
models of the left ventricle in patients with EAH is
given in table 1. Insignificant reduction of CS LPHD
were observed both in men and women with CG LV
1,3 and 1,2 times (p=0, 054-0,056) in case of CS
LHPD in IA increase in patients with hypertrophic
geometric models (EH LV and CH LV) 1,4 times
(p=0,036-0,039) and 1,5 and 1,6 times (p< 0,01), cor-
respondingly. IA in patients with CH LV exceeded
the same in patients with CR LV 1,2 times (p=0,05).
Analysis of indices changes of lipid metabolism
with regard for haplotypes of genes ACE (I/D) and
eNOS (T894G) (table 2) is the evidence of probably
greater IA in carriers of DD/TG and DD/GG-hap-
lotypes than in those with II/GG-haplotype by 18,7%
(p≤0,05), respectively. Reliable distinctions were not
revealed as to other indices. Essential changes were
not observed too (p>0,05) at lipid profile analysis
depending on geometry of the LV myocardium ac-
cording to haplotypes genes ACE (I/D) and eNOS
(T894G).
Epidemiological analysis of the indices of an inc-
rease of absolute and relative risks of dislipidemia
onset in presence of unfavourable hypertrophic mo-
dels of the LV myocardium depending on nine hap-
lotypes or their combinations with calculation of the
ratio of risks, chances and corresponding confidence
intervals is given in table 3. Carrier state of mutant
D-allele gene ACE and T-allele gene eNOS in
haplotype (ID/TT, ID/TG, DD/TG) is unfavourable
factor and increases the risk of dislipidemia onset in
EAH patients with EH LV, or CH LV 2,57, 4,21 and
3,86 times, correspondingly. Instead of, the presence
of II-genotype of gene ACE in haplotype, with
regard for genotypes of gene eNOS, decreases the
given risk to the probability of 0,32-0,95 time
(OR=0,12-1,17), but combination of wild homozygous
I-allele of gene ACE and G-allele of eNOS gene (II/
GG haplotype) is projective as to the hyper-
cholesterolemia development in patients with
unfavourable patterns of LVH (OR=0,12) and makes
risk chances of dislipidemia the lowest in the
population of patients with EAH (p=0,05) under
study. A reliable dependence on MM LV  with GCS
Îðèã³íàëüí³ äîñë³äæåííÿ
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Table 2
Lipid profile in EAH patient depending on haplotypes of ACE (ID) genes  and eNOS
(T894G)
Genotypes’ combination of ACE (I/D) and eNOS (T894G) 
Lipid indices 
ІІ/TT, n=2  II/TG, n=13  II/GG, n=9  
GCS, mmol/l 5,58±0,65 5,31±0,43 5,37±0,52  
CV LPHD, mmol/l 1,20±0,24 1,23±0,25 1,26±0,12  
CS LPHD, mmol/l 3,44±0,43 3,25±0,37 3,26±0,50 
TG, mmol/l 1,58±0,32 1,66±0,28 1,67±0,22 
IA, cond.un. 3,61±0,56 3,50±0,71 3,21±0,24 DD/TG DD/GG 
 ID/TT, n=7 (%) ID/TG, n=31 (%) ID/GG, n=24 
GCS, mmol/l 5,86±0,90 5,59±0,69 5,65±0,45 
CS LPHD, mmol/l 1,17±0,19 1,21±0,13 1,23±0,10 
CS LPHD, mmol/l 3,73±0,47 3,55±0,38 3,56±0,57 
ТG, mmol/l 1,65±0,30 1,64±0,21 1,66±0,20 
ІА, cond.un. 4,0±0,45 3,62±0,55 3,59±0,78 
 DD/TT, n=0  DD/TG, n=20  DD/GG, n=14 
GCS, mmol/l – 5,74±0,42 5,68±0,89 
CS LPHD, mmol/l – 1,18±0,15 1,20±0,10 
CS LPLD, mmol/l – 3,67±0,44 3,69±0,55 
ТG, mmol/l – 1,63±0,29 1,62±0,19 
ІА, cond. un. – 3,86±0,30 3,78±0,32 
Notes: 1. Commentary of abbreviations are corresponding to Table 1. 2. Probability of indices’ differences 
relatively to certain haplotype is raised to the degree (p≤0,05) 
 Table 3
Genotype combinations of  I/D polymorphism of gene ACE and T849G of eNOS gene as
risk factors of dislipidemia onset in EAH patients with hypertrophic models (eccentric/
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Note: ARI (absolute risk increase) / ARR (absolute risk reduction) – increase / decrease of absolute risk; RRI 
(relative risk increase) / RRR (relative risk reduction) – increase / decrease of relative risk; Re1R (relative 
risk) – relative risk 
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and IA, but only in patients of high and very high car-
dio-vascular risk with a damage of target organs and
evident complications (r=0,51-0,60, p≤0,042-0,005)
was revealed when analyzing correlative relations. In
patients with EAH III MM LV was also associated
with the level of CS LP HD (r=0,47; p=0,035) and
BWY (r=0,49, p=0,028). The evidence of the direct
reliable relation of MM LV in carriers of D-allele MT
with BWY (r=0,39-0,41; p=0,044-0,039), in carriers
of DD-genotype - with GCS (r=0,60; p=0,005), CS
LPTLD and CS LPHD (r=0,42-0,53; p=0,039-0,017)
correspondingly was established depending on allele
state of ACE gene. In T-allele carriers gene eNOS
MM LV correlated reliably only with BWY (r=0,32-
0,39; p=0,044-0,02), but in GG-genotype carriers with
CS LPHD (r=0,75; p=0,021) with the reverse depen-
dence upon CS LPHD (r=0,81; p=0,011).
Thus, to our mind, the data obtained are the re-
sults of realizations of genetically determinated cli-
nical phenotype EAH that is accompanied by struc-
tural-functional change of the LV myocardium and
associated changes of lipid metabolism that gives the
possibility to determine groups of dislipidemia risk
depending upon haplotype and geometric model of
LVH.
Conclusions
1. Carriers of DD-genotype of gene ACE accor-
ding to the content increase of CS LPHD and athe-
rogenecity index 1,3 times (p<0,05) are the risk
groups of lipid profile disorder in patients with EAH.
2. Genetically stipulated risk of dislipidemia onset
in patients with EAH in presence of unfavourable
eccentric and concentric LVH and mutations of ACE
genes (homozygous, or heterozygous presence of D-
allele in haplotype) and eNOS (ID/TT, ID/TG, DD/
TD haplotypes) increase 2,57-3,86 times. Com-
bination of the wild I-allele of ACE gene and G-allele
of e NOS gene (II/GG, II/TG haplotypes is projective
as to hypercholesterolemia development in patients
with unfavourable LVH patterns (OR=0,12-0,94) and
makes chances of dislipidemia risk the lowest in popu-
lation of patients with EAH under study.
3. MMLV probably correlates: with GCS and IA
in patients with EAH of the II and III st., with BWY
in patients with EAH III st., D-allele carriers of ACE
gene and T-allele of eNOS gene, with GCS, CS
LPTDD and CS LPLD in patients with DD-geno-
type and CS LPLD and CS LPHD in patients with
GG-genotype of eNOS gene.
  Perspectives of further research lie in
studying the condition of vascular arterial bloods-
tream in patients with EAH depending on polymor-
phism of the chosen genes, severity of hypertension
and geometry to the left ventricle miocardium.
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ÏÀÒÎÃÅÍÅÒÈ×ÍÈÉ ÇÂ'ßÇÎÊ ÇÌ²Í Ë²Ï²ÄÍÎÃÎ
ÏÐÎÔ²ËÞ ² ÌÎÄÅËÅÉ Ã²ÏÅÐÒÐÎÔÎÂÀÍÎÃÎ
Ì²ÎÊÀÐÄÀ Ë²ÂÎÃÎ ØËÓÍÎ×ÊÀ ÇÀËÅÆÍÎ Â²Ä
ÏÎË²ÌÎÐÔ²ÇÌÓ ÃÅÍ²Â ÀÑÅ (I/D), ENOS (T894G) Ó
ÕÂÎÐÈÕ ÍÀ ÅÑÅÍÖ²ÀËÜÍÓ Ã²ÏÅÐÒÅÍÇ²Þ
Î.Â. Êóøí³ð, Ë.Ï. Ñèäîð÷óê, Î.Ì. ²ôòîäà, À.Ð. Ñèäîð÷óê
Ìåòà äîñë³äæåííÿ. Âñòàíîâèòè çàëåæí³ñòü çì³í
ë³ï³äíîãî ïðîô³ëþ ó õâîðèõ íà åñåíö³éíó àðòåð³àëüíó
ã³ïåðòåíç³þ (ÅÀÃ) â³ä âèäó ã³ïåðòðîô³¿ ë³âîãî øëóíî÷êà
(ÃËØ) òà ïîë³ìîðô³çìó ãåí³â àíã³îòåíçèí-ïåðåòâî-
ðþâàëüíîãî ôåðìåíòó (ÀÑÅ, I/D) ³ åíäîòåë³àëüíî¿ îêñèäó
àçîòó ñèíòàçè (eNOS, T894G).
Äèçàéí/ï³äõ³ä. Ó ïðîñïåêòèâíîìó äîñë³äæåíí³ âçÿëî
ó÷àñòü 120 õâîðèõ íà ÅÀÃ ²-²²² ñòàä³é òÿæêîñò³: 12,5% (15)
îñ³á ³ç ÅÀÃ ², 60,0% (72) ³ç ÅÀÃ ²², 27,5% (33) ³ç ÅÀÃ ²²² ñò.;
48,3% (58) æ³íîê ³ 51,7% (62) ÷îëîâ³ê³â, ñåðåäí³é â³ê
52,91±9,24 ðîêó, òðèâàë³ñòü çàõâîðþâàííÿ â³ä 2 äî 28 ðîê³â;
êîíòðîëüíà ãðóïà - 20 ïðàêòè÷íî çäîðîâèõ îñ³á. Ìàñó
ì³îêàðäà ËØ (ÌÌËØ) îö³íþâàëè ìåòîäîì Åõî-ÊÃ. Ë³ï³äè
ïëàçìè äîñë³äæóâàëè íà ñïåêòðîôîòîìåòð³, àíàë³çóâàëè
â³äïîâ³äíî äî ðåêîìåíäàö³é ESC, ESH (2009). Àëåë³
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Ðåçóëüòàòè äîñë³äæåííÿ. Ãðóïàìè ðèçèêó ïîðóøåííÿ
ë³ï³äíîãî ïðîô³ëþ ó õâîðèõ íà ÅÀÃ º íîñ³¿ DD-ãåíîòèïó
ãåíà ÀÑÅ çà çðîñòàííÿì âì³ñòó õîëåñòåðîëó ë³ïîïðîòå¿ä³â
íèçüêî¿ ãóñòèíè òà ³íäåêñó àòåðîãåííîñò³ ó 1,3 ðàçà (ð<0,05).
Ãåíåòè÷íî çóìîâëåíèé ðèçèê ïîÿâè äèñë³ï³äåì³é ó õâîðèõ íà
ÅÀÃ çà íàÿâíîñò³ íåñïðèÿòëèâèõ åêñöåíòðè÷íî¿ òà êîí-
öåíòðè÷íî¿ ÃËØ ³ ìóòàö³¿ ãåí³â ÀÑÅ òà eNOS (ID/TT, ID/TG,
DD/TG ãàïëîòèïè) çðîñòàº ó 2,57-3,86 ðàçà (OR=2,57-3,86).
Êîìá³íàö³ÿ äèêî¿ ²-àëåë³ ãåíà ÀÑÅ òà G-àëåë³ ãåíà eNOS (II/
GG, II/TG ãàïëîòèïè) º ïðîòåêòèâíèì ùîäî ðîçâèòêó
ã³ïåðõîëåñòåðîëåì³¿ ó õâîðèõ ³ç íåñïðèÿòëèâèìè ïàòåðíàìè
ÃËØ (OR=0,12-0,94) ³ ðîáèòü øàíñè ðèçèêó äèñë³ï³äåì³é
íàéíèæ÷èìè â îáñòåæóâàí³é ïîïóëÿö³¿ õâîðèõ íà ÅÀÃ
(ð=0,05).
Îáìåæåííÿ äîñë³äæåííÿ/íàñë³äêè. Îáìåæåííÿ çóìîâëåí³
îñîáëèâîñòÿìè ïðîâåäåííÿ ëàáîðàòîðíî-ä³àãíîñòè÷íèõ
äîñë³äæåíü.
Îðèã³íàëüí³ñòü / çíà÷åííÿ. Îðèã³íàëüíå äîñë³äæåííÿ áåç
ïðîòîòèïó, íàäàº ïàòîãåíåòè÷í³ äàí³ äëÿ ðàííüî¿ ä³àãíîñòèêè
òà ïðîô³ëàêòèêè ìåòàáîë³÷íèõ ïîðóøåíü çà íàÿâíîñò³/
â³äñóòíîñò³ ÃËØ ó õâîðèõ íà ÅÀÃ.
Êëþ÷îâ³ ñëîâà: àðòåð³àëüíà ã³ïåðòåíç³ÿ, ãåíåòè÷íèé
ïîë³ìîðô³çì, ë³ï³äíèé ïðîô³ëü, ã³ïåðòðîô³ÿ ë³âîãî
øëóíî÷êà.
ÏÀÒÎÃÅÍÅÒÈ×ÅÑÊÀß ÑÂßÇÜ ÈÇÌÅÍÅÍÈÉ
ËÈÏÈÄÍÎÃÎ ÏÐÎÔÈËß È ÌÎÄÅËÅÉ
ÃÈÏÅÐÒÐÎÔÈÐÎÂÀÍÍÎÃÎ ÌÈÎÊÀÐÄÀ ËÅÂÎÃÎ
ÆÅËÓÄÎ×ÊÀ Â ÇÀÂÈÑÈÌÎÑÒÈ ÎÒ
ÏÎËÈÌÎÐÔÈÇÌÀ ÃÅÍÎÂ ÀÑÅ (I/D), ENOS (T894G)
Ó ÁÎËÜÍÛÕ ÝÑÑÅÍÖÈÀËÜÍÎÉ ÃÈÏÅÐÒÅÍÇÈÅÉ
Î.Â. Êóøíèð, Ë.Ï. Ñèäîð÷óê, Î.Ì. Èôòîäà,
À.Ð. Ñèäîð÷óê
Öåëü èññëåäîâàíèÿ. Èññëåäîâàòü îñîáåííîñòè
èçìåíåíèé ëèïèäíîãî ïðîôèëÿ ó áîëüíûõ ýññåíöèàëüíîé
àðòåðèàëüíîé ãèïåðòåíçèåé (ÝÀÃ) â çàâèñèìîñòè îò âèäà
ãèïåðòðîôèè ëåâîãî æåëóäî÷êà (ÃËÆ) è ïîëèìîðôèçìà
ãåíîâ àíãèîòåíçèí-ïðåâðàùàþùåãî ôåðìåíòà (ÀÑÅ, I/D) è
ýíäîòåëèàëüíîé îêèñè àçîòà ñèíòàçû (eNOS, T894G).
Äèçàéí/ïîäõîä. Â ïðîñïåêòèâíîì èññëåäîâàíèè ïðèíÿëè
ó÷àñòèå 120 áîëüíûõ ÝÀÃ ²-²²² ñòàäèé òÿæåñòè, ñðåäè íèõ ó
12,5% (15) - ÝÀÃ ², ó 60,0% (72) - ÝÀÃ ²², ó 27,5% (33) - ÝÀÃ
²²² ñò.; 48,3% (58) æåíùèí è 51,7% (62) ìóæ÷èí, ñðåäíèé
âîçðàñò 52,91±9,24 ãîäà, äëèòåëüíîñòü çàáîëåâàíèÿ îò 2 äî
28 ëåò; êîíòðîëüíàÿ ãðóïïà - 20 ïðàêòè÷åñêè çäîðîâûõ ëèö.
Ìàññó ìèîêàðäà ËÆ (ÌÌËÆ) îïðåäåëÿëè ìåòîäîì Ýõî-ÊÃ.
Ëèïèäíûé ïðîôèëü ïëàçìû èññëåäîâàëè íà ñïåêòðî-
ôîòîìåòðå, àíàëèçèðîâàëè ñîîòâåòñòâåííî ðåêîììåíäàöèé
ESC, ESH (2009). Àëëåëè ïîëèìîðôíûõ ó÷àñòêîâ ãåíîâ ÀÑÅ
(I/D), eNOS (T894G) - ñ ïîìîùüþ ÏÖÐ àíàëèçà.
Ðåçóëüòàòû èññëåäîâàíèÿ. Ñðåäè áîëüíûõ ÝÀÃ ãðóïïàìè
ðèñêà èçìåíåíèé ëèïèäíîãî ïðîôèëÿ ñ óâåëè÷åíèåì ñîäåð-
æàíèÿ õîëåñòåðèíà ëèïîïðîòåèäîâ íèçêîé ïëîòíîñòè è
èíäåêñà àòåðîãåííîñòè â 1,3 ðàçà (ð <0,05) ÿâëÿþòñÿ íîñè-
òåëè DD-ãåíîòèïà ãåíà ÀÑÅ. Ãåíåòè÷åñêè îáóñëîâëåííûé
ðèñê ïîÿâëåíèÿ äèñëèïèäåìèé ó áîëüíûõ ÝÀÃ ïðè íàëè÷èè
íåáëàãîïðèÿòíûõ ýêñöåíòðè÷íîé è êîíöåíòðè÷åñêîé ÃËÆ è
ìóòàöèè ãåíîâ ÀÑÅ è eNOS (ID /TT, ID/TG, DD/TG ãàïëî-
òèïû) âîçðàñòàåò â 2,57-3,86 ðàçà (OR = 2,57-3,86).
Êîìáèíàöèÿ äèêîé I-àëëåëè ãåíà ÀÑÅ è G-àëëåëè ãåíà eNOS
(II/GG, II/TG ãàïëîòèïû) ïðåäóïðåæäàåò ðàçâèòèå
ãèïåðõîëåñòåðîëåìèè ó áîëüíûõ ñ íåáëàãîïðèÿòíûìè
ïàòòåðíàìè ÃËÆ (OR = 0,12-0,94) è äåëàåò øàíñû ðèñêà
äèñëèïèäåìèé íàèáîëåå íèçêèìè â îáñëåäóåìîé ïîïóëÿöèè
áîëüíûõ ÝÀÃ (ð=0,05).




áåç ïðîòîòèïà ïðåäîñòàâëÿåò ïàòîãåíåòè÷åñêèå äàííûå äëÿ
ðàííåé äèàãíîñòèêè è ïðîôèëàêòèêè ìåòàáîëè÷åñêèõ
íàðóøåíèé ïðè íàëè÷èè / îòñóòñòâèè ÃËÆ ó áîëüíûõ ÝÀÃ.
Êëþ÷åâûå ñëîâà: àðòåðèàëüíàÿ ãèïåðòåíçèÿ, ãåíå-
òè÷åñêèé ïîëèìîðôèçì, ëèïèäíûé ïðîôèëü, ãèïåðòðîôèÿ
ëåâîãî æåëóäî÷êà.
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